Estimation the medical cost of multiple sclerosis in Iran; 2019-2020.
Economic burden
Iran
Medical cost
Multiple sclerosis
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
02 Feb 2022
02 Feb 2022
Historique:
received:
01
05
2021
accepted:
25
01
2022
entrez:
3
2
2022
pubmed:
4
2
2022
medline:
5
2
2022
Statut:
epublish
Résumé
Due to the high and increasing economic burden of chronic diseases, including Multiple sclerosis (MS), we aimed to investigate the medical cost of MS in Iran. This is a descriptive cross-sectional study which conducted using comprehensive national prescription data from Iran's Health Insurance Organization (IHIO) and rehabilitation data from Ministry of Health and Iran Welfare Organization. The time period considered for this study was 2019-2020. In order to calculate the medical cost of MS, the cost-of-illness (COI) method was used based on the prevalence-based approach and the cost of medications, determining and diagnosing the MS risk, follow-up and rehabilitation was estimated. The total medical cost of MS in Iran in 2019-2020 was estimated at $238,124,160, which medications and rehabilitation services had the largest share in the medical cost of MS in Iran with 80 and 19%, respectively, and the cost share of determining and diagnosing of the disease risk accounted for about less than 1%. The total medication cost was estimated to be equal to $192,298 thousand. The total cost of determining and diagnosing of the MS risk was estimated at $348,574 and the total cost of rehabilitation services for all MS subgroups in 2019-2020 was estimated at $45,477,205. Results of calculating the medical cost of MS in Iran in 2019-2020 showed a significant burden on the Iranian health care system and society, among which the medication cost had the largest share, which requires serious attention of health system policymakers.
Sections du résumé
BACKGROUND
BACKGROUND
Due to the high and increasing economic burden of chronic diseases, including Multiple sclerosis (MS), we aimed to investigate the medical cost of MS in Iran.
METHODS
METHODS
This is a descriptive cross-sectional study which conducted using comprehensive national prescription data from Iran's Health Insurance Organization (IHIO) and rehabilitation data from Ministry of Health and Iran Welfare Organization. The time period considered for this study was 2019-2020. In order to calculate the medical cost of MS, the cost-of-illness (COI) method was used based on the prevalence-based approach and the cost of medications, determining and diagnosing the MS risk, follow-up and rehabilitation was estimated.
RESULTS
RESULTS
The total medical cost of MS in Iran in 2019-2020 was estimated at $238,124,160, which medications and rehabilitation services had the largest share in the medical cost of MS in Iran with 80 and 19%, respectively, and the cost share of determining and diagnosing of the disease risk accounted for about less than 1%. The total medication cost was estimated to be equal to $192,298 thousand. The total cost of determining and diagnosing of the MS risk was estimated at $348,574 and the total cost of rehabilitation services for all MS subgroups in 2019-2020 was estimated at $45,477,205.
CONCLUSIONS
CONCLUSIONS
Results of calculating the medical cost of MS in Iran in 2019-2020 showed a significant burden on the Iranian health care system and society, among which the medication cost had the largest share, which requires serious attention of health system policymakers.
Identifiants
pubmed: 35109835
doi: 10.1186/s12913-022-07551-z
pii: 10.1186/s12913-022-07551-z
pmc: PMC8812215
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
137Informations de copyright
© 2022. The Author(s).
Références
Semin Immunol. 2009 Dec;21(6):328-33
pubmed: 19775910
Immunol Rev. 2012 Jul;248(1):87-103
pubmed: 22725956
BMC Neurol. 2021 Oct 15;21(1):400
pubmed: 34654397
Eur J Neurol. 2006 Jul;13(7):700-22
pubmed: 16834700
J Neurol Neurosurg Psychiatry. 1997 Jun;62(6):553-61
pubmed: 9219738
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
BMC Neurol. 2020 May 23;20(1):205
pubmed: 32446303
BMC Health Serv Res. 2021 Mar 20;21(1):257
pubmed: 33743679
Mult Scler Relat Disord. 2020 Sep;44:102247
pubmed: 32554286
Med Care. 1996 Dec;34(12 Suppl):DS197-9
pubmed: 8969326
Milbank Mem Fund Q Health Soc. 1982 Summer;60(3):429-62
pubmed: 6923138
Neuropsychiatr Dis Treat. 2017 Nov 01;13:2737-2745
pubmed: 29138568
Mult Scler. 2012 May;18(5):662-8
pubmed: 21965424
Eur J Health Econ. 2018 Dec;19(9):1243-1257
pubmed: 29680926
PLoS One. 2019 May 14;14(5):e0216646
pubmed: 31086393
J Epidemiol Community Health. 1995 Dec;49(6):563-9
pubmed: 8596089
Neurol Sci. 2015 Feb;36(2):227-34
pubmed: 25109816
Pharmacoeconomics. 2006;24(9):869-90
pubmed: 16942122
Mult Scler. 2020 Dec;26(14):1816-1821
pubmed: 33174475
Health Promot Chronic Dis Prev Can. 2017 Feb;37(2):37-48
pubmed: 28273039
Lancet Neurol. 2019 Mar;18(3):269-285
pubmed: 30679040
Pract Neurol. 2015 Aug;15(4):273-9
pubmed: 26101071